Navigation Links
Groupe Athena, Inc. Releases 3rd Quarter Financials, Continues Strong Revenue And Earnings Growth
Date:4/10/2013

MUMBAI, India, April 10, 2013 /PRNewswire/ -- Groupe Athena, Inc. (OTCPink: GATA) today released their quarterly report for the three months ending March 30, 2013. Revenues for the period were $13,378,452 which represents a 29% increase over the same period in 2012. Net after tax income for the period was $1,319,920 or $.03 per share.

Cumulative revenue for the trailing twelve months (ttm) was $53,569,759 with per share earnings of $.11 per share.

Cash reserves remain strong and continue to grow and long term debt remains virtually non-existent as the Company prepares to outfit its recently purchased new testing facility. The company reports it is still committed to funding all capital expenditures entirely from internal cash accruals without any shareholder dilution or debt increases.

Company Chairman, D. Purohit stated, "At Groupe Athena we strive to create shareholder value as a component of our business model and our current price to earnings ratio and share valuation is a fraction of our industry peers which is indicative of those efforts. The Indian pharmaceutical industry continues to be a global leader and experience superior growth which is creating new pathways for Groupe Athena to follow."

As previously stated, the company plans to apply for listing on the NASDAQ Bulletin Board quotation system with the completion of the audit for this fiscal year ending June 30, 2013.

To review the complete quarterly report please go to www.otcmarkets.com/stock/GATA/quote and click on "Financials"

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.
Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 17 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.


'/>"/>
SOURCE Groupe Athena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Enters Multi Year Contractual Relationship With Major Bangladesh Pharmaceutical Manufacturer
2. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
3. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
4. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
5. US B12 Shots releases New Article about Vitamin B12 Injections and Benefits
6. Watchdog Organization Releases Toolkit to Help Employers Navigate Pharmacy Benefits Contracts
7. CIVCO Releases Non-Invasive Stereotactic Radiosurgery (SRS) Solution for Head and Brain Tumors
8. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
9. ECRI Institute Releases C-Suite Watch List of Top 10 Hospital Technology Issues for 2013
10. Medical Marijuana, Inc. Releases 2012 Annual Share Holders Report and First Ever Corporate Revenue Forecasts
11. Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):